📊 MGNX Key Takeaways
Is Macrogenics Inc. (MGNX) a Good Investment?
MacroGenics is a pre-profitability pharmaceutical company with minimal revenue ($20.8M) unable to cover operating expenses (-$33.4M), resulting in severe operating losses and negative free cash flow (-$36.2M). With only ~$66.5M in cash against an annual burn rate of ~$36M and no clear path to profitability, the company faces a critical liquidity crisis within 18-24 months without successful drug commercialization or significant capital infusion.
MacroGenics shows weak underlying fundamentals, with nearly flat revenue but deeply negative operating and net margins, substantial cash burn, and worsening net income and EPS. While the company still has solid near-term liquidity and no meaningful long-term debt, its low equity base, negative free cash flow, and lack of profitable growth materially weaken financial quality.
Why Buy Macrogenics Inc. Stock? MGNX Key Strengths
- Adequate liquidity position with $66.5M cash providing operational runway
- Solid current ratio (1.90x) and quick ratio (1.80x) indicate short-term solvency
- Low long-term debt burden reduces financial risk relative to liabilities
- Strong near-term liquidity with current ratio of 5.10x and quick ratio of 4.92x
- No meaningful long-term debt, limiting balance-sheet leverage risk
- Revenue base remains sizable at $149.50M despite only a slight YoY decline
MGNX Stock Risks: Macrogenics Inc. Investment Risks
- Extreme cash burn rate ($36.2M FCF burn vs $66.5M total cash = ~18-month runway)
- Massive operating losses (-$33.4M) on minimal revenue ($20.8M) indicates business model is not viable at current scale
- Liabilities ($196.7M) constitute 90% of total assets with equity cushion only $21.2M; vulnerability to capital structure failure
- Negative interest coverage (-6.8x) and stagnant revenue growth (-0.3% YoY) indicate deteriorating operational health
- Persistent operating losses and a -48.7% operating margin indicate an unsustainable earnings profile
- Negative operating cash flow and deeply negative free cash flow show heavy ongoing cash consumption
- Very weak equity position relative to losses, reflected in ROE of -134.2%, reduces financial flexibility
Key Metrics to Watch
- Cash burn rate trend and time-to-runway calculation
- Revenue growth rate - any acceleration would indicate product commercialization progress
- Operating loss reduction - path to gross margin breakeven on current revenue
- Capital raise events - next financing round size and dilution terms
- Quarterly operating cash burn relative to cash and equivalents
- Revenue durability and operating margin improvement
Macrogenics Inc. (MGNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Macrogenics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MGNX Profit Margin, ROE & Profitability Analysis
MGNX vs Healthcare Sector: How Macrogenics Inc. Compares
How Macrogenics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Macrogenics Inc. Stock Overvalued? MGNX Valuation Analysis 2026
Based on fundamental analysis, Macrogenics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Macrogenics Inc. Balance Sheet: MGNX Debt, Cash & Liquidity
MGNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Macrogenics Inc.'s revenue has grown significantly by 43% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.15 indicates the company is currently unprofitable.
MGNX Revenue Growth, EPS Growth & YoY Performance
MGNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $13.2M | -$36.8M | $-0.58 |
| Q3 2025 | $72.8M | $16.8M | $0.27 |
| Q2 2025 | $10.8M | -$36.3M | $-0.57 |
| Q1 2025 | $9.1M | -$41.0M | $-0.65 |
| Q3 2024 | $10.4M | $17.6M | $0.28 |
| Q2 2024 | $10.8M | $19.5M | $0.31 |
| Q1 2024 | $9.1M | -$38.0M | $-0.61 |
| Q3 2023 | $10.4M | $17.6M | $0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Macrogenics Inc. Dividends, Buybacks & Capital Allocation
MGNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Macrogenics Inc. (CIK: 0001125345)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779308039.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779308034.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779308028.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779308021.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779308015.xml | View → |
❓ Frequently Asked Questions about MGNX
What is the AI rating for MGNX?
Macrogenics Inc. (MGNX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MGNX's key strengths?
Claude: Adequate liquidity position with $66.5M cash providing operational runway. Solid current ratio (1.90x) and quick ratio (1.80x) indicate short-term solvency. ChatGPT: Strong near-term liquidity with current ratio of 5.10x and quick ratio of 4.92x. No meaningful long-term debt, limiting balance-sheet leverage risk.
What are the risks of investing in MGNX?
Claude: Extreme cash burn rate ($36.2M FCF burn vs $66.5M total cash = ~18-month runway). Massive operating losses (-$33.4M) on minimal revenue ($20.8M) indicates business model is not viable at current scale. ChatGPT: Persistent operating losses and a -48.7% operating margin indicate an unsustainable earnings profile. Negative operating cash flow and deeply negative free cash flow show heavy ongoing cash consumption.
What is MGNX's revenue and growth?
Macrogenics Inc. reported revenue of $20.8M.
Does MGNX pay dividends?
Macrogenics Inc. does not currently pay dividends.
Where can I find MGNX SEC filings?
Official SEC filings for Macrogenics Inc. (CIK: 0001125345) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MGNX's EPS?
Macrogenics Inc. has a diluted EPS of $-0.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MGNX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Macrogenics Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MGNX stock overvalued or undervalued?
Valuation metrics for MGNX: ROE of -173.5% (sector avg: 15%), net margin of -177.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MGNX stock in 2026?
Our dual AI analysis gives Macrogenics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MGNX's free cash flow?
Macrogenics Inc.'s operating cash flow is $-35.8M, with capital expenditures of $344.0K. FCF margin is -174.0%.
How does MGNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -177.0% (avg: 12%), ROE -173.5% (avg: 15%), current ratio 1.90 (avg: 2).